Brief: Cloudbreak Pharma Withdraws IND Application For CBT-009 Phase 3 Trial In China
19/03/2026 15:26
March 19 (Reuters) - Cloudbreak Pharma Inc 2592.HK: WITHDRAWS IND APPLICATION FOR PHASE 3 TRIAL IN CHINA TO REASSESS CLINICAL DEVELOPMENT STRATEGY FOR CBT-009 EXPECTS PHASE 3 MRCT COMPLETION FOR CBT-001 IN Q3 2026 Further company coverage: 2592.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cloudbreak Pharma
See all newsHong Kong watchdog tells firms how to cooperate in raids as scrutiny of share sales grows
Hong Kong watchdog tells firms how to cooperate in raids as scrutiny of share sales grows
Brief: Cloudbreak Pharma Says FDA Completes Safety Review Of CBT-358 Ind Application With No Objection
Brief: Cloudbreak Pharma Enters Share Subscription Agreement With Arc Group International For Up To $15 Mln
Brief: Cloudbreak Pharma Announces Final Patient Visit for 12-Month Efficacy Endpoint in Phase 3 Study of CBT-001 as a Potential Treatment for Pterygium